<!DOCTYPE html>

<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df1d/8803322/0861034a52b7/jci-132-151109-g084.jpg"/> </div> <div class="text-side"> <h1>Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma.</h1> <p>The orally active SOX18 inhibitor Sm4 suppresses vessel formation in a murine model for IH.HemSCs were pretreated with 10% DMSO in PBS or 10 μM Sm4 for 24 hours, suspended in Matrigel with 10% DMSO in PBS or 5 μM Sm4 and injected into nude mice, with 2 implants per mouse (n = 12). The mice were treated with 25 mg/kg Sm4 or an equivalent volume of 10% DMSO in PBS once a day by oral gavage. Matrigel implants harvested after 7 days are shown in the top panels. Scale bars: 10 mm. H&amp;E staining (middle panels) and anti–human CD31 staining (red; lower panels) showed a significant reduction in vessel density in the implants from Sm4-treated mice compared with those from control mice. Nuclei were counterstained with DAPI (blue). Scale bars: 100 μm. Graphs show quantification of vessels/mm2 in the H&amp;E-stained sections (top) and human CD31+ vessels/mm2 (bottom). P values were calculated by 2-tailed, unpaired Students’ t test. Data show the mean ± SD. Data were collected for 2 implants in each of 6 mice, leading to an observation sample size of 12 per group. </p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34874911/" target="_blank">34874911</a></p><p>Type: Benign, Category: Vascular</p>
</div> </div></div></body></html>